azacitidine + R-CHOP

Azacitidine + R-CHOP is an investigational combination therapy for aggressive B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma. It combines oral azacitidine (CC‑486), a hypomethylating agent that inhibits DNA methyltransferase and induces genome-wide hypomethylation to reverse chemoresistance, with the standard immunochemotherapy regimen known as R‑CHOP. The latter consists of rituximab (a CD20-targeting monoclonal antibody), cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic), vincristine (a vinca alkaloid), and prednisone (a corticosteroid). This combination aims to enhance the efficacy of standard chemotherapy by epigenetically priming tumor cells before cytotoxic treatment. Early-phase studies have shown promising response rates and acceptable safety in previously untreated intermediate-to-high-risk DLBCL or grade 3B/transformed follicular lymphoma[1][2][3][4].

Brand names

Vidaza + R-CHOPCC-486 + R-CHOP

Other names

oral azacitidine + R-CHOPCC-486 plus rituximab-cyclophosphamide-doxorubicin-vincristine-prednisoneCC486 plus rituximab-cyclophosphamide-doxorubicin-vincristine-prednisoneCC 486 plus rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone